Table 1 The relationships between SKA3 expression and clinicopathological features in prostate cancer patients in the TCGA database
Characteristic | Low expression of SKA3 (n = 249) | High expression of SKA3 (n = 250) | P value |
|---|---|---|---|
Age, n (%) | 0.080 | ||
< = 60 | 122 (54.5%) | 102 (45.5%) | |
> 60 | 127 (46.2%) | 148 (53.8%) | |
T stage, n (%) | < 0.001 | ||
T2 | 124 (65.6%) | 65 (34.4%) | |
T3 | 118 (40.4%) | 174 (59.6%) | |
T4 | 2 (18.2%) | 9 (81.8%) | |
N stage, n (%) | 0.036 | ||
N0 | 171 (49.3%) | 176 (50.7%) | |
N1 | 28 (35.4%) | 51 (64.6%) | |
M stage, n (%) | 1.000 | ||
M0 | 223 (49%) | 232 (51%) | |
M1 | 1 (33.3%) | 2 (66.7%) | |
Race, n (%) | 0.101 | ||
Asian | 4 (33.3%) | 8 (66.7%) | |
Black or African American | 35 (61.4%) | 22 (38.6%) | |
White | 202 (48.7%) | 213 (51.3%) | |
Residual tumor, n (%) | 0.006 | ||
R0 | 173 (54.9%) | 142 (45.1%) | |
R1 | 59 (39.9%) | 89 (60.1%) | |
R2 | 2 (40%) | 3 (60%) | |
Zone of origin, n (%) | 0.348 | ||
Central Zone | 2 (50%) | 2 (50%) | |
Overlapping / Multiple Zones | 50 (39.7%) | 76 (60.3%) | |
Peripheral Zone | 69 (50.4%) | 68 (49.6%) | |
Transition Zone | 3 (37.5%) | 5 (62.5%) | |
PSA (ng/ml), n (%) | 0.102 | ||
< 4 | 214 (51.6%) | 201 (48.4%) | |
>=4 | 9 (33.3%) | 18 (66.7%) | |
Gleason score, n (%) | < 0.001 | ||
6 | 36 (78.3%) | 10 (21.7%) | |
7 | 142 (57.5%) | 105 (42.5%) | |
8 | 28 (43.8%) | 36 (56.2%) | |
9 | 42 (30.4%) | 96 (69.6%) | |
10 | 1 (25%) | 3 (75%) | |
PFI event, n (%) | < 0.001 | ||
Alive | 218 (53.8%) | 187 (46.2%) | |
Dead | 31 (33%) | 63 (67%) |